Equity
€440,915 ▲ 77.0%
Equity rose in 2024 from €249,123 to €440,915.
PEHLIMED
Lifetime
12 annual accounts with figures on one time axispeak €471,901 (2024)
€471,901▲ 29.9%
lowest -€139,229 (2022)
€191,793▲ 47.0%
peak €494,129 (2021)
€440,915▲ 77.0%
€517,232▼ 20.0%
peak 1 FTE (2018)
-not published
Board1 name since 2021
1 director
Documentsfilings and deeds
30-09-202561 days late
2024micro format
Gross margin from €363,397 to €471,901Result from €130,450 to €191,793Equity from €249,123 to €440,915Debts from €646,782 to €517,232Cash from €211 to €2,392
Key points
from the 2024 annual accountsTurnover
≈ €720,000 estimated
The accounts state no turnover.
Staff
7 employees on 31-12-2024
In 2024, 3 people joined and 7 left.
Liquidity
1.80 was 1.35 in 2023
Short-term debts fell from €624,381 to €507,132.
Filings
12 annual accounts 105 days past the deadline
2025 accounts not filed: deadline was 31-07-2026.
Position in the sector
€191,793
Higher net result than 88% of companies in human health. Sector median €58,795 · 19,766 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 34,721 companies had the same profile as PEHLIMED has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,721 companies, not a prediction for PEHLIMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
New establishment in Anderlecht
Bergense Steenweg 1105
Amendment of the articles
Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0500843464
Capital conversion · Amendment of the articles · Legal-form change · Resignations & appointments
Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PEHLIMED Anderlecht | €1.0m | €471,901 | 46.0% | - |
| maison medicale perspective Anderlecht | €1.0m | €515,607 | 92.9% | 5.7 |
| Dr TIGRA Anderlecht | €0.8m | €424,430 | 2.5% | - |
| EPITOPE Woluwe-Saint-Lambert | €1.1m | €551,238 | 38.3% | - |
| DR. REFAT SHARAFEDIN, ALGEMENE GENEESKUNDE Brussels | €1.2m | €380,027 | 58.5% | - |
| MEDIFAR Forest | €0.8m | €392,332 | 89.9% | - |
| HUISARTSENWACHTPOST GAOZ Genk | €1.1m | €460,392 | 58.5% | 5.7 |
These companies have the same main activity as PEHLIMED: general medical practice (NACE 86210). They are comparable in size and age: total assets between €756,000 and €1.2m, founded between 2008 and 2014.
Official details
Source: KBO- Status
- Active since 16-11-2012Normal situation
- Activity
- General medical practiceNACE 86210
- Establishment units
- 2.214.391.8181070 Anderlecht, since 29-11-2012
- 2.387.315.4011070 Anderlecht, since 01-03-2026
- Financial year end
- 31 December
- Peppol
- Reachable since 03-09-2025
Annual accounts 2024
- €958,147▲ 6.9%
- Employeeson 31-12-2024
- 7▲ 40.0%
- Filing
- Filed on 30-09-2025
Insights on PEHLIMED
PEHLIMED files the micro format. That format states no turnover. The gross margin rose from €101,211 in 2013 to €471,901 in 2024.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PEHLIMED
- What is the company number of PEHLIMED?
- The company number of PEHLIMED is 0500.843.464. The VAT number is the same number with BE in front: BE 0500.843.464.
- Where is PEHLIMED based?
- The registered office is at Bergense Steenweg 984, 1070 Anderlecht.Company details
- What does PEHLIMED do?
- According to the KBO register, the main activity is general medical practice (NACE 86210).
- What is the legal form of PEHLIMED?
- PEHLIMED is a private limited company (BV).
- When was PEHLIMED founded?
- PEHLIMED was founded on 16-11-2012.
- Is PEHLIMED still active?
- Yes, PEHLIMED is an active enterprise in the KBO register.
- How many employees does PEHLIMED have?
- PEHLIMED had an average of 5.5 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- What is the turnover of PEHLIMED?
- The turnover in financial year 2024 is ≈ €720,000. This figure is estimated from the gross margin of €471,901 and 38 comparable companies (NACE 862). It probably lies between €630,000 and €910,000.
- Is PEHLIMED profitable?
- In financial year 2024, PEHLIMED made a profit of €191,793.
- Where can I find the annual accounts of PEHLIMED?
- PEHLIMED filed 12 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.